
Capricor Faces Investor Scrutiny Following FDA Efficacy Dispute
Capricor shares plummeted between 60% and 70% on July 27, 2026, after FDA briefing documents directly challenged the company’s claims regarding the cardiac efficacy of its drug, Deramiocel. The sudden market contraction has prompted the law firm Levi & Korsinsky to launch an investigation into potential securities law violations.






















